# Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/VANI/vivani-medical-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: VANI
Company: Vivani Medical
Source: Vivani Medical
Published: 2026-05-13 20:05 EST
Original Source URL: https://investors.vivani.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-14 20:03 EST — [Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026](https://biopharmsignal.com/news/VANI/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-15-2026-793033b6) — Source: Vivani Medical
- 2026-07-07 11:35 EST — [Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management](https://biopharmsignal.com/news/VANI/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-min-9e9275ac) — Source: Vivani Medical
- 2026-07-02 12:00 EST — [Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.](https://biopharmsignal.com/news/VANI/vivani-announces-entry-into-merger-agreement-between-wholly-owned-subsidiary-cor-743c93e1) — Source: Vivani Medical
- 2026-06-26 11:30 EST — [Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker](https://biopharmsignal.com/news/VANI/vivani-medical-announces-appointment-of-august-j-moretti-to-board-of-directors-a-38ca0d85) — Source: Vivani Medical
- 2026-06-25 11:30 EST — [Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management](https://biopharmsignal.com/news/VANI/vivani-medical-receives-regulatory-approval-for-the-initiation-of-slim-1-a-phase-040f1891) — Source: Vivani Medical
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)